The Experimental Study In Apoptosis Of Androgen Independent Prostate Cancer Cells Induced By TNE And PDTC

PURPOSE: To investigate novel therapeutic strategies for androgen independent prostate cancer. METHODS: Human AIPC cell line PC-3 were routinely propagated in monolayer culture in a humidified incubator at 37℃ in a 5%C02195% air atmosphere. Cells were grown in RPMI-1 640 medium supplemented with 20% heat-inactivated bobby calf serum. When the cell number was enough, SCID mice were injected subcutaneously with PC-3 cells (2.0) (106 cells/mouse in 0.2ml of 0.9%NaCl) harvested by quick trypsinization of ongoing culture. Then the SCID mice were raised in SPF grade room. The SCID mice were divided random into four groups after a palpable primary tumor was present. Control mice received 0.9%NaCl subcutaneously (0.2m1/mouse). TNF α was injected in tumor inner for group B(200μg/kg). C group was injected intraperitoneally with PDTC(200mg/kg).D group received TNF α and PDTC in the same way. Therapy was administered qod. Solid tumors were taken out and measured with dial caliper and then the obtained tumors were fixed for apoptosis assay after 28 days. RESULTS: The therapeutic groups compared with the control showed significantly different in size and the percentage of apoptotic cells (P <0.01) and the tumor inhibition rates were 80.8%(B group), 64.6%(C group), and 93. 1%(D group). The tumor volume was significantly smaller after therapy than before therapy in D group (P <0.01), but showed not in B group or C group (P > 0.05). In the course of therapy, one mouse died in the control group. CONCLUSIONS: The growth of androgen independent prostate III cancer cells was significantly inhibited by TNF α or PDTC. But the more significant therapeutic efficiency was detected by the combination of TNF a and PDTC. It indicates that the mechanism underlying TNF α growth inhibition in PC-3 cells, whose growth is androgen independent, is to induce apoptotic cell death and PDTC enhances the ability of TNF α.